These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34151801)

  • 41. Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment.
    Stricker NH; Lundt ES; Albertson SM; Machulda MM; Pudumjee SB; Kremers WK; Jack CR; Knopman DS; Petersen RC; Mielke MM
    J Alzheimers Dis; 2020; 76(1):261-274. PubMed ID: 32538841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.
    Zhao A; Li Y; Yan Y; Qiu Y; Li B; Xu W; Wang Y; Liu J; Deng Y
    Transl Neurodegener; 2020 Aug; 9(1):30. PubMed ID: 32741361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota.
    Li B; He Y; Ma J; Huang P; Du J; Cao L; Wang Y; Xiao Q; Tang H; Chen S
    Alzheimers Dement; 2019 Oct; 15(10):1357-1366. PubMed ID: 31434623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease.
    Olazarán J; Gil-de-Gómez L; Rodríguez-Martín A; Valentí-Soler M; Frades-Payo B; Marín-Muñoz J; Antúnez C; Frank-García A; Acedo-Jiménez C; Morlán-Gracia L; Petidier-Torregrossa R; Guisasola MC; Bermejo-Pareja F; Sánchez-Ferro Á; Pérez-Martínez DA; Manzano-Palomo S; Farquhar R; Rábano A; Calero M
    J Alzheimers Dis; 2015; 45(4):1157-73. PubMed ID: 25649659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TNF receptors are associated with tau pathology and conversion to Alzheimer's dementia in subjects with mild cognitive impairment.
    Zhao A; Li Y; Deng Y;
    Neurosci Lett; 2020 Nov; 738():135392. PubMed ID: 32947003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.
    Silva D; Cardoso S; Guerreiro M; Maroco J; Mendes T; Alves L; Nogueira J; Baldeiras I; Santana I; de Mendonça A
    J Alzheimers Dis; 2020; 74(3):785-796. PubMed ID: 32083585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis of Cognitive Impairment Compatible with Early Diagnosis of Alzheimer's Disease. A Bayesian Network Model based on the Analysis of Oral Definitions of Semantic Categories.
    Guerrero JM; Martínez-Tomás R; Rincón M; Peraita H
    Methods Inf Med; 2016; 55(1):42-9. PubMed ID: 25925692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Periodontal Status and Saliva Metabolic Signature in Patients with Alzheimer's Disease.
    Yang Y; Lv J; Bai H; Ren L; Yang J; Ding Y; Liu C; Chen X
    J Alzheimers Dis; 2023; 95(2):603-613. PubMed ID: 37424468
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Computer-Assisted Speech Analysis in Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study from Shanghai, China.
    Qiao Y; Xie XY; Lin GZ; Zou Y; Chen SD; Ren RJ; Wang G
    J Alzheimers Dis; 2020; 75(1):211-221. PubMed ID: 32250297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum Phosphatidylethanolamine and Lysophosphatidylethanolamine Levels Differentiate Alzheimer's Disease from Controls and Predict Progression from Mild Cognitive Impairment.
    Llano DA; Devanarayan V;
    J Alzheimers Dis; 2021; 80(1):311-319. PubMed ID: 33523012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer's disease.
    Eteleeb AM; Novotny BC; Tarraga CS; Sohn C; Dhungel E; Brase L; Nallapu A; Buss J; Farias F; Bergmann K; Bradley J; Norton J; Gentsch J; Wang F; Davis AA; Morris JC; Karch CM; Perrin RJ; Benitez BA; Harari O
    PLoS Biol; 2024 Apr; 22(4):e3002607. PubMed ID: 38687811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
    Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
    Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry.
    González-Domínguez R; García A; García-Barrera T; Barbas C; Gómez-Ariza JL
    Electrophoresis; 2014 Dec; 35(23):3321-30. PubMed ID: 25136972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease.
    Zhang B; Ferman TJ; Boeve BF; Smith GE; Maroney-Smith M; Spychalla AJ; Knopman DS; Jack CR; Petersen RC; Kantarci K
    J Neuroimaging; 2015; 25(2):269-274. PubMed ID: 25039916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Degree of cognitive impairment does not signify early versus late mild cognitive impairment: confirmation based on Alzheimer's disease polygenic risk.
    Elman JA; Vuoksimaa E; Franz CE; Kremen WS;
    Neurobiol Aging; 2020 Oct; 94():149-153. PubMed ID: 32623261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-Throughput Metabolomics for Discovering Potential Metabolite Biomarkers and Metabolic Mechanism from the APPswe/PS1dE9 Transgenic Model of Alzheimer's Disease.
    Yu J; Kong L; Zhang A; Han Y; Liu Z; Sun H; Liu L; Wang X
    J Proteome Res; 2017 Sep; 16(9):3219-3228. PubMed ID: 28753016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.